Pharma R&D Today

Ideas and Insight supporting all stages of Drug Discovery & Development

Select category
Search this blog

How will Brexit effect Multinationals and Pharmaceutical Companies?

Posted on June 30th, 2016 by

Pharma R&D

brexit-1478082_1280

One of the most stunning upsets to happen in global politics in decades transpired on June 23 when the people of the United Kingdom voted to leave the European Union. Continue reading “How will Brexit effect Multinationals and Pharmaceutical Companies?” »

The Fundamentals of Good Data Stewardship

Posted on June 29th, 2016 by

Pharma R&D

library

Bioactivity data is not in short supply. The days of limited availability of data on compounds and biological targets are long behind us. Continue reading “The Fundamentals of Good Data Stewardship” »

What Does the 2016 US Election Mean For Pharma?

Posted on June 28th, 2016 by

Pharma R&D

R_D_Solutions_Blog_Politics_DIGITAL

With summer, the 2016 U.S. Presidential Election is now truly heating up as we have presumptive nominees from the two major political parties. While we are hearing a lot about issues like national security and immigration from Republican nominee Donald Trump and Democratic nominee Hillary Clinton, those working in the pharmaceutical industry may be wondering how their sector will be affected by the eventual winner. Continue reading “What Does the 2016 US Election Mean For Pharma?” »

The Changing Competencies of Pharmacovigilance Leadership

Posted on June 27th, 2016 by

Pharmacovigilance

connect-20333_1920

Significant transformations happened over the last decade regarding the role of pharmacovigilance (PV) departments in pharmaceutical organizations. This had a tremendous impact not only on the technical knowledge needed, but more importantly on the non-technical competencies that should be required for any PV role in pharma. Continue reading “The Changing Competencies of Pharmacovigilance Leadership” »

Linking Disease Biology to Novel Drug Targets

Posted on June 22nd, 2016 by

Pharma R&D

science-1182713_1920

Discovering novel drug targets is complicated, and we all know about their low success rate in the clinic. Continue reading “Linking Disease Biology to Novel Drug Targets” »

Advancing the Development and Clinical Use of Biomarkers

Posted on June 21st, 2016 by

Pharma R&D

Biomarker-based patient selection for clinical trials

Biomarker-based patient selection for clinical trials, a hallmark of precision medicine, is gaining traction. On Monday June 6, a team of researchers reported at the American Society of Clinical Oncology annual meeting and in an online paper in JAMA Oncology that biomarker selection results in better outcomes in Phase l trials. Continue reading “Advancing the Development and Clinical Use of Biomarkers” »

  1. 1
  2. 36
  3. 37
  4. 38
  5. 39
  6. 40
  7. 51


About this Blog

iStock_000019748868_Full

The Elsevier Pharma R&D blog provides insight and opinion on topics related to pharmaceutical research and development, namely: big data, target identification, new drug discovery, drug safety monitoring, risk mitigation and regulatory compliance. We serve the community of chemists, scientists, drug safety specialists, educators and students interested in pharmaceutical R&D.

Editor’s note: The views and opinions expressed are those of the author and do not necessarily reflect the views of Elsevier,  its affiliates and sponsors or its parent company, Reed Elsevier.